Gujarat Kidney IPO Analyzed
This report summarizes the recent Initial Public Offering (IPO) of Gujarat Kidney and Super Speciality, a company offering shares for the first time. Investors showed a lot of interest, with significantly more shares requested than were initially available. The IPO was a big success, heavily subscribed and raising substantial funds for future growth.
Key Points
- Strong Demand: Investors bought 5.21 times more shares than offered.
- Raised Funds: The IPO brought in Rs 250.8 crore through the sale of new shares.
- Investment Uses: Funds will be used for hospitals, equipment, and debt repayment.
- Promoter Ownership: Promoters own 99.1% of the company pre-IPO.
- Anchor Investors: Rs 100.01 crore was raised from anchor investors before the IPO.
- Financial Performance: The company reported Rs 4.84 crore net profit and Rs 15.26 crore income.
About Gujarat Kidney and Super Speciality
Gujarat Kidney and Super Speciality provides healthcare services in Gujarat, India. They operate seven hospitals and four pharmacies. The company focuses on a wide range of medical treatments, including kidney transplants and advanced surgeries. They provide services like internal medicine, surgery, and specialized treatments.
IPO Details
The IPO was open for bidding from December 22nd to December 24th, 2025, with a price range of Rs 108 to Rs 114 per share. The company planned to raise up to Rs 250.8 crore through selling new shares. This money will go towards building new hospitals, buying medical equipment, and paying back some of its debts.
Funding Breakdown
The company plans to use the money raised for several important things: buying the Parekhs Hospital in Ahmedabad, paying for the Ashwini Medical Centre, buying more shares in a related company, funding new building projects, buying robotic equipment for its hospital in Vadodara, paying off debts, and for general business expenses. The promoters hold a large percentage of the company’s stock.
Anchor Investors
Before the IPO, the company raised Rs 100.01 crore by selling shares to 10 major investors. This helps to stabilize the stock price when the IPO starts. The shares were sold at Rs 114 each.
Financial Results (Q1 FY2026)
For the three months leading up to June 30th, 2025, the company made a profit of Rs 4.84 crore and had income of Rs 15.26 crore. Revenue is divided between government bodies, insurance companies, and individual patients.
Ultimately, this IPO represents a significant investment opportunity for Gujarat Kidney and Super Speciality’s future growth.
